Anti-BCMA CAR-T cell therapy became the first cellular immunotherapy approved by the U.S. Food and Drug Administration (FDA) in 2021 for the treatment of multiple myeloma, achieving unprecedented clinical efficacy (19, 20). The gene discussed is TNFRSF17; the disease is AL amyloidosis.